Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction

Area of Science:

• Immunogenetics
• Transplantation immunology
• Genomic medicine

Background:

• Primary graft dysfunction (PGD) pathogenesis involves conserved biologic pathways.
• Previous studies on recipient genetic variation in PGD were limited to candidate gene analyses.

Purpose of the Study:

• Identify genetic variants increasing PGD risk in lung transplant recipients.
• Utilize a two-phase, large-scale genotyping approach for variant discovery.

Main Methods:

• Phase 1: Large-scale candidate gene association study in the Lung Transplant Outcomes Group cohort.
• Phase 2: Functional evaluation of selected variants and bioinformatics screening.
• Analysis included 680 lung transplant recipients after genetic data quality control.

Main Results:

• 17 variants significantly associated with PGD identified.
• Four variants within prostaglandin E2 family genes were notable.
• PTGES2 coding variant (rs700799) and PTGER4 promoter/intronic variants (rs4434423, rs17190674, rs17190675) showed strong association (P < 9.3 × 10(-5)).
• rs4434423 in PTGER4 associated with differential regulatory T cell suppressive function.

Conclusions:

• Genetic variations in prostaglandin E2 synthetic and signaling pathways are implicated in PGD.
• Further research for replication and functional insight is warranted.
• Findings highlight the role of specific genetic variants in PGD pathogenesis and immune regulation.